ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Partner program
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint746,904 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical companyWädenswilGlycoEra AG
GlycoEra AG Logo
Verified· 3 sourcesTrust Score
Summary

About the company

GlycoEra AG develops bifunctional biologics designed to selectively direct disease-causing extracellular and membrane proteins for degradation. Its therapeutic programs initially focus on autoimmune diseases and the circulating proteins that drive them.

AI-generated
Offering

Products & services

Industry:Pharmaceutical company
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

GlycoEra AG

✓ Offered5
Development of Precision Therapeutics
Development of novel biologics for the selective removal of disease-causing proteins, with an initial focus on autoimmune diseases and other protein-driven conditions.
Protein Targeting and Degradation
Protein targeting and degradation of circulating extracellular and membrane proteins to remove disease-causing proteins quickly, deeply and selectively from circulation.
Autoimmune Disease Programs
Programs for the treatment of autoimmune diseases, in particular against circulating autoantibodies, with the first program GE8820 for pathogenic IgG4 autoantibodies.
Platform for Extracellular Protein Degraders
Platform for the development of bifunctional biologics for the degradation of extracellular and membrane-bound proteins; designed for fast, deep and selective target engagement.
Partnerships for Pipeline Development
Partnerships with industrial companies to expand the impact of the platform and to develop additional programs against circulating proteins.
Trust & reputation

ranQ Trust Score of GlycoEra AG: 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 58% · As of November 2026

Without public customer reviews the score stays capped.

GlycoEra AG has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
GlycoEra AG scores 81.5 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.70.212%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.90.07%
GlycoEra AG scores 85.0 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).85.022%
GlycoEra AG scores 52.7 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.68.64%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.36.74%
Qualifications+0.00

GlycoEra AG reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 58%, so the score is backed by part of the criteria. As of November 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Press

Media

May 27, 2025Media
GlycoEra AG raises $130 Million to advance therapies for autoimmune diseases
startupticker.ch
January 8, 2024Media
Bristol Myers Squibb invests in GlycoEra
startupticker.ch
January 19, 2021Media
LimmaTech launches spin-out for drug development
startupticker.ch

Knowledge

No knowledge articles yet

Once GlycoEra AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

GlycoEra AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank GlycoEra AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of GlycoEra AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Einsiedlerstrasse 34
8820 Wädenswil
Opening hours
Mon
09:00 - 16:00
Tue
09:00 - 16:00
Wed
09:00 - 16:00
Thu
09:00 - 16:00
Fri
09:00 - 16:00
Sat
Closed
Sun
Closed

At a glance

Legal form
Corporation
UID
CHE-477.046.648
Founded
2020 · 6 years
Last commercial register change
March 19, 2026
Employees
51 to 100
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    MP
    Molecular Partners AG
    Schlieren
    AT
    Axanton Technology GmbH
    Schlieren
    LT
    Linkster Therapeutics AG
    Zurich
    TT
    Tandem Therapeutics AG
    Schlieren
    SB
    Swiss Bioscience GmbH
    Schlieren
    MA
    Mabylon AG
    Schlieren
    NT
    NovaGo Therapeutics AG
    Schlieren
    NT
    Numab Therapeutics AG
    Horgen